Zandelisib

N/A

Report date: 2023/05/05 17:37:02
NME

Base Information

Drug NameZandelisib
Drug Alias NameKinase program MEI PharmaPWT-143ME-401
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase delta inhibitors
TargetsPhosphatidylinositol 3 kinase delta
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesTaiwan +[15] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPathway
China Registration ClassN/A

Develop Information

Active CompaniesKyowa Kirin Co Ltd
Inactive CompaniesKyowa Kirin IncMei Pharma Inc
Active IndicationsLymphoma, B-Cell
Inactive IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[7] 

Other Information

ATC CodeN/A
Related LinksN/A